Aprea Therapeutics, Inc. Capital Expenditures
Aprea Therapeutics, Inc. (APRE) reported Capital Expenditures of $15.40 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-12
- Aprea Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Aprea Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $0.00.
- Aprea Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-06-30 was $7.50K.
- Aprea Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-03-31 was $7.98K.
- Aprea Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $15.48K, a 83.37% decline from fiscal 2023.
- Aprea Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $93.09K.
- Aprea Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2020 was $25.71K, a 16.80% decline from fiscal 2019.
- Aprea Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2019 was $30.90K, a 734.71% increase from fiscal 2018.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.40K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $7.50K derived: sum of 3 quarters · filed 2026-03-16 | $15.48K 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $7.50K derived: sum of 2 quarters · filed 2025-11-12 | $15.48K 10-Q · filed 2025-11-12 | $22.63K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $7.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $15.48K 10-Q · filed 2025-08-12 | $22.63K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $7.98K 10-Q · filed 2025-05-14 | $15.13K derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $7.15K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $93.09K 10-K · filed 2025-03-25 | ||
| 2023-09-30 | $85.94K 10-Q · filed 2024-11-07 | |||
| 2020-12-31 | $16.29K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $15.56K derived: sum of 2 quarters · filed 2023-03-30 | $13.54K derived: sum of 3 quarters · filed 2023-03-30 | $25.71K 10-K · filed 2023-03-30 |
| 2020-09-30 | -$725.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$2.75K derived: sum of 2 quarters · filed 2021-11-08 | $9.42K 10-Q · filed 2021-11-08 | $23.89K derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | -$2.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $10.14K 10-Q · filed 2021-08-12 | $24.61K derived: sum of 3 quarters · filed 2022-03-15 | $34.86K derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $12.16K 10-Q · filed 2021-05-06 | $26.63K derived: sum of 2 quarters · filed 2022-03-15 | $36.88K derived: sum of 3 quarters · filed 2022-03-15 | |
| 2019-12-31 | $14.47K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $24.71K derived: sum of 2 quarters · filed 2022-03-15 | $30.90K 10-K · filed 2022-03-15 | |
| 2019-09-30 | $10.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $16.43K 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $6.19K 10-Q · filed 2020-08-11 | |||
| 2018-12-31 | -$804.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $3.70K 10-K · filed 2021-03-16 | ||
| 2018-09-30 | $4.51K 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |